Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism (original) (raw)
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
Jack Hirsh
The Journal of Urology, 1998
View PDFchevron_right
Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism
Martin Prins
Current Opinion in Pulmonary Medicine, 1998
View PDFchevron_right
Low-molecular-weight heparin (LMWH) in the treatment of thrombosis
René G Holzheimer
European journal of medical research, 2004
View PDFchevron_right
Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients
Soyon Lee
Journal of Hospital Medicine, 2012
View PDFchevron_right
Low-Molecular-Weight Heparins for the Prevention and Treatment of Venous Thromboembolism
Gia Dice
Military Medicine, 2001
View PDFchevron_right
Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis
shailesh kakde
PubMed, 2013
View PDFchevron_right
Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism
Susan Solymoss, Jeffrey Ginsberg
JAMA, 2006
View PDFchevron_right
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study
Henry Eriksson
Circulation, 1989
View PDFchevron_right
Secondary Prevention of Venous Thromboembolism: A Role for Low-Molecular-Weight Heparin
Manuel Monreal
Pathophysiology of Haemostasis and Thrombosis, 1998
View PDFchevron_right
Therapeutic Application of Subcutaneous Low-Molecular-Weight Heparin in Acute Venous Thrombosis
Hermann Bratsch
Pathophysiology of Haemostasis and Thrombosis, 1990
View PDFchevron_right
Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry
Monserrat Jimenez
Annals of Hematology, 2007
View PDFchevron_right
Comparison of low-molecular weight heparins to unfractionated heparin
Robert Berent
European Heart Journal, 2001
View PDFchevron_right
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
Sergio Siragusa
The American Journal of Medicine, 1996
View PDFchevron_right
Low-molecular-weight heparin for thromboprophylaxis
Giuseppe Camporese
Current opinion in pulmonary medicine, 2009
View PDFchevron_right
Low molecular weight heparin in prevention of perioperative thrombosis
Francois Chapuis
BMJ, 1992
View PDFchevron_right
Outpatient treatment of venous thromboembolism using low molecular weight heparins. An overview
Miltiadis Matsagkas
2004
View PDFchevron_right
Low-Molecular-Weight Heparin Use with Thrombolysis: Is it Effective and Safe? Ten Years' Clinical Experience
Leyla Saglam
Respiration, 2013
View PDFchevron_right
PROPHYLAXIS OF THROMBOSIS WITH LOW-MOLECULAR-WEIGHT HEPARIN (LMWH
René G Holzheimer
eur j med res, 2004
View PDFchevron_right
Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs
Jodi Segal, Jerry Krishnan, Michael Streiff
The American Journal of Medicine, 2003
View PDFchevron_right
A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Melissa Forgie
Archives of Internal Medicine, 2005
View PDFchevron_right
Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism
Fred Verzijlbergen
2004
View PDFchevron_right
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
Bo Risberg, Jan Frisell
British Journal of Surgery, 1986
View PDFchevron_right
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
James Dalen
Chest, 1992
View PDFchevron_right
Prophylaxis of postoperative thromboembolism with low molecular weight heparins
Peer Wille-Jørgensen
British Journal of Surgery, 1993
View PDFchevron_right
Low-molecular-weight or Unfractionated Heparin in Venous Thromboembolism: The Influence of Renal Function
Pedro Gallego
The American Journal of Medicine, 2013
View PDFchevron_right
[Thrombophilia, thromboembolism and the use of the unfractionated and low-molecular-weight heparins]
Abraham Majluf-cruz
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
View PDFchevron_right
Orally Administered Unfractionated Heparin With Carrier Agent Is Therapeutic for Deep Venous Thrombosis
M. Gonze
Circulation, 2000
View PDFchevron_right
Preclinical studies on a low molecular weight heparin
Ahmad ridhani ahsan
Thrombosis Research, 1996
View PDFchevron_right
Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500versus 5000 Xal units in 2070 patients
Mats Hedberg, Jan Frisell
British Journal of Surgery, 1995
View PDFchevron_right
Optimal Dosing of Subcutaneous Unfractionated Heparin for the Treatment of Deep Vein Thrombosis
Jeffrey Ginsberg
Thrombosis Research, 2000
View PDFchevron_right
Antithrombotic and bleeding effects of a low molecular weight heparin fraction
Giangiacomo Torri
Biochemical Pharmacology, 1985
View PDFchevron_right